Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre-dialysis chronic kidney disease or end-stage renal disease

Int J Urol. 2023 Oct;30(10):931-933. doi: 10.1111/iju.15221. Epub 2023 Jun 6.

Authors

Kensuke Bekku¹, Naoya Nagasaki¹, Ichiro Tsuboi², Atsushi Takamoto³, Satoshi Katayama¹, Motoo Araki¹

Affiliations

¹ Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
² Department of Urology, Shimane University Hospital, Izumo, Japan.
³ Department of Urology, Fukuyama City Hospital, Fukuyama, Japan.

PMID: 37278602
DOI: 10.1111/iju.15221

No abstract available

MeSH terms

Carcinoma, Renal Cell* / complications
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / pathology
Dialysis
Humans
Immune Checkpoint Inhibitors / adverse effects
Kidney Failure, Chronic* / complications
Kidney Failure, Chronic* / therapy
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / pathology
Renal Dialysis
Renal Insufficiency, Chronic* / complications

Substances

Immune Checkpoint Inhibitors